Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sarah Gheuens Sells 2,909 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 2,909 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $97,567.86. Following the sale, the insider now directly owns 56,988 shares in the company, valued at approximately $1,911,377.52. The trade was a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Agios Pharmaceuticals Stock Up 2.9%

Shares of NASDAQ AGIO traded up $0.94 during trading on Thursday, hitting $33.65. The company had a trading volume of 274,744 shares, compared to its average volume of 653,135. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of 2.99 and a beta of 0.73. The stock has a fifty day simple moving average of $31.03 and a two-hundred day simple moving average of $32.38. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The firm had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. On average, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AGIO shares. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Scotiabank cut their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $58.60.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in AGIO. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $49,290,000. SCS Capital Management LLC purchased a new position in Agios Pharmaceuticals in the 1st quarter valued at $17,905,000. Adage Capital Partners GP L.L.C. boosted its stake in Agios Pharmaceuticals by 145.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company's stock worth $21,770,000 after purchasing an additional 440,000 shares during the last quarter. Palo Alto Investors LP acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth $8,104,000. Finally, Paradigm Biocapital Advisors LP purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $9,084,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.